Status:
RECRUITING
Effect of a Pharmacist-led Multifaceted Intervention on Treatment Outcomes in Hypertensive Patients
Lead Sponsor:
Xijing Hospital
Collaborating Sponsors:
The First Affiliated Hospital of Zhengzhou University
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Conditions:
Hypertension
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The objective of this cluster randomized controlled trial is to evaluate the effectiveness of a pharmacist-led multifaceted intensive blood pressure intervention on poorly controlled hypertensive pati...
Detailed Description
This cluster randomized trial is conducted in eight tertiary hospitals of China, and we planned to enroll 100 participants at each hospital. The eight hospitals will be randomly divided into an interv...
Eligibility Criteria
Inclusion
- Inclusion Criteria (subjects must meet all of the following criteria to be included):
- 1\) age 18-80 years;
- 2\) patients with hypertension (diagnostic criteria: defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg according to the "Guidelines for the prevention and treatment of hypertension in China in 2023", based on the blood pressure measurement of three times on different days), who are currently taking anti-hypertensive medication and are judged by the research physician to have poor blood pressure control;
- 3\) able to use smartphones and WeChat proficiently, and can communicate and upload pictures proficiently;
- 4\) able to take care of yourself and communicate normally, and willing to cooperate with the research physician to complete the study and follow-up;
- 5\) permanent residents of the city where the center is located;
- 6\) voluntarily participate and sign the informed consent form
- Exclusion Criteria(subjects will be excluded if they meet any of the following criteria):
- 1\) patients with advanced disease (such as patients undergoing dialysis or liver failure), or with a life expectancy of less than 2 years as determined by the research physician;
- 2\) combined with psychiatric disease, cognitive impairment, communication disorder, or inability to cooperate with the researchers;
- 3\) combined with cerebrovascular disease, stroke, severe liver and kidney dysfunction, severe heart failure, cancer and history of organ transplantation, etc.;
- 4\) patients who are pregnant, breastfeeding, or planning to conceive in the next 2 years.
Exclusion
Key Trial Info
Start Date :
June 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT06558877
Start Date
June 20 2025
End Date
December 31 2027
Last Update
July 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xijing hospital
Xi'an, Shaanxi, China, 710032